Patients with T3-4aN + M0 G/GEJ adenocarcinoma were randomly assigned (1:1:1) to receive perioperative treatment with SOXRC, SOXR, or SOX. The primary end points were pathologic complete response (pCR ...
Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose–Positron Emission Tomography OPTICAL was a randomized, ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.
Please provide your email address to receive an email when new articles are posted on . Talazoparib (Talzenna, Pfizer), a poly(ADP)-ribose polymerase (PARP) inhibitor, also appeared generally ...
Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...
Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment DESTINY-Breast11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results